19 results on '"Luznik, L"'
Search Results
2. 6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT)
3. Post-transplantation Cyclophosphamide (Cy) as a single agent for GVHD prophylaxis after HLA matched related and unrelated bone marrow transplantation
4. Rapid Reconstitution Of The Regulatory T Cell Compartment After High Dose Cyclophosphamide Immunosuppression Prevents The Development Of GVHD After Allogeneic BMT
5. Rapid Reconstitution Of The Regulatory T Cell Compartment After High Dose Cyclophosphamide Immunosuppression Prevents The Development Of GVHD After Allogeneic BMT
6. Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity
7. 87 Residual host chemerism and pattern of antigen expression influence the fate of adoptively transferred allogenic T cells
8. 320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras
9. 99 Solid tumor vaccines elicit distinct immune responses from host versus donor T cells in mixed chimeras created by non-myeloablative allogeneic stem cell transplantation (NST)
10. Dosing of Busulfan in Overweight and Obese Patients Compared to Normal Weight Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
11. Post-Transplant Cyclophosphamide (PT/Cy) Preserves Effector (Teff) and Regulatory (Treg) T Cells During Early Immune Reconstitution After Allogeneic Bone Marrow Transplantation
12. Immune Reconstitution After Nonmyeloablative, T-Cell Replete, HLA-Haploidentical BMT With Post-Transplantation Cyclophosphamide
13. Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation (haplo-BMT) With Post-Transplant High-Dose Cyclophosphamide (Cy) in Patients With Severe Hemoglobinopathies
14. Requirement and Plasticity of CD4+Foxp3+ T Regulatory Cells (Tregs) in GVHD Prevention With High-Dose Posttransplant Cyclophosphamide (HiCy) in Mice and Humans
15. Secondary Systemic Immunosuppressants (SSI) After Myeloablative HLA Matched Related And Unrelated Bone Marrow Transplantation (BMT) Using High Dose Cyclophosphamide (HiCy) As Sole GVHD Prophylaxis
16. Secondary Systemic Immunosuppressants (SSI) After Myeloablative HLA Matched Related And Unrelated Bone Marrow Transplantation (BMT) Using High Dose Cyclophosphamide (HiCy) As Sole GVHD Prophylaxis
17. Role of STAT3 Signaling in GVHD and GVL
18. After MHC-matched allografting, host-derived langerhans cells (LCs) persist in skin and cutaneous lymph nodes in the steady-state and are the targets of DLI-mediated alloresponse
19. After MHC-matched allografting, host-derived langerhans cells (LCs) persist in skin and cutaneous lymph nodes in the steady-state and are the targets of DLI-mediated alloresponse
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.